SUBSIDIARIES

Stemedica has developed multiple operating companies designed to focus on specific medical conditions. Each operating company maintains its own leadership team, supported by a focused Board of Directors and Advisory Board, which brings specialized expertise to each subsidiary.

  • CardioCell, LLC
  • Specializing in Cardiology
  • StemCutis, LLC
  • Specializing in Dermatology
  • Stemedica International, SA
  • Specializing in Alzheimer’s & Dementia
  • StemProtein, LLC
  • Manufacturer of Stem Cell-derived “Factors”
  • Stemedica Asia Pte, Ltd
  • Asia Pacific Region Business Development

Stemedica’s Bio-Smart Technology™ Platform supports the advancement of its products through its operating companies which are focused on multiple medical conditions.

 

CardioCell LLC is a biotechnology company that explores therapeutic applications of unique patented ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell has an exclusive worldwide license from Stemedica Cell Technologies Inc. for the exploration of therapeutic cardiovascular indications, including acute myocardial Infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD).

StemCutis, LLC is a biotechnology company that develops cosmetic products and dermatology therapies for photoaged skin (cutaneous photoaging) and hair restoration using unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) and stem cell factors manufactured under cGMP conditions. StemCutis is an operating company of Stemedica Cell Technologies, Inc. StemCutis has an exclusive, worldwide license to use Stemedica’s unique and patented stem cell technology for indications in the skin care and skin therapeutics fields.

Stemedica International S.A. is biotechnology company that explores therapeutic applications of patented stem cells to treat degenerative diseases. In 2012 the Swiss Commission for Technology and Innovation (CTI) awarded Stemedica International and the Laboratory of Biomedical Optics at the École Polytechnique Fédérale de Lausanne (EPFL) a grant to develop practical applications of stem cell therapies and brain imaging for Alzheimer’s disease. The grant is designed to facilitate and accelerate transition from academic and pre-clinical research to the clinical phase and, ultimately, commercial use of stem cell therapies in treating Alzheimer’s disease.

Stemedica International is a subsidiary of Stemedica Cell Technologies Inc. and has exclusive rights to manufacture and apply Stemedica’s allogeneic, ischemia-tolerant mesenchymal (itMSC) and neural (itNSC) stem cell lines and stem cell factors to create therapies for the treatment and prevention of Alzheimer’s disease and vascular dementia. The company also has Swissmedic licenses to import, export and distribute Stemedica’s cell lines worldwide for human use in approved clinical trials.

The company has headquarters in Lausanne, Switzerland, and a U.S. office in San Diego, California.

Stemedica Asia Pte Ltd is headquartered in Singapore and serves the Asia Pacific region with advanced stem cell technologies. Stemedica Asia is a subsidiary of Stemedica Cell Technologies, Inc., and has the exclusive rights to market and represent the parent company’s interest in the Asia Pacific region.

Stemedica Asia is devoted to bringing stem cell therapeutics and products that help people to live longer and healthier lives. Currently, Stemedica Asia is working to accelerate the commercialization of its stem cell technologies as it partners with prestigious organizations in Singapore, China, Japan, South Korea and several other Asian Pacific markets.

StemProtein manufactures Stem Cell Factors (SCFs) for pharmaceutical use in a variety of treatment, preventative, and/or health-maintenance products including nasal sprays, eye drops, intravenous injections, wound dressings, and creams.

StemProtein is a subsidiary of Stemedica Cell Technologies, Inc. whose patented platform technology produces SCFs from Stemedica’s ischemic-tolerant mesenchymal stem cells (itMSCs).